130 related articles for article (PubMed ID: 36272185)
1. Scaffold hopping via ring opening enables identification of acyclic compounds as new complement Factor D inhibitors.
Zhang W; Wu M; Vadlakonda S; Juarez L; Cheng X; Muppa S; Chintareddy V; Vogeti L; Kellogg-Yelder D; Williams J; Polach K; Chen X; Raman K; Babu YS; Kotian P
Bioorg Med Chem; 2022 Nov; 74():117034. PubMed ID: 36272185
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
[TBL] [Abstract][Full Text] [Related]
3. Discovery and Development of the Oral Complement Factor D Inhibitor Danicopan (ACH-4471).
Wiles JA; Galvan MD; Podos SD; Geffner M; Huang M
Curr Med Chem; 2020; 27(25):4165-4180. PubMed ID: 31573880
[TBL] [Abstract][Full Text] [Related]
4. The role of properdin in the assembly of the alternative pathway C3 convertases of complement.
Hourcade DE
J Biol Chem; 2006 Jan; 281(4):2128-32. PubMed ID: 16301317
[TBL] [Abstract][Full Text] [Related]
5. Quantification of the pro-form of human complement component factor D (adipsin).
Henriksen ML; Nielsen C; Pedersen D; Andersen GR; Thiel S; Palarasah Y; Hansen SWK
J Immunol Methods; 2022 Aug; 507():113295. PubMed ID: 35679953
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo.
Lorthiois E; Anderson K; Vulpetti A; Rogel O; Cumin F; Ostermann N; Steinbacher S; Mac Sweeney A; Delgado O; Liao SM; Randl S; Rüdisser S; Dussauge S; Fettis K; Kieffer L; de Erkenez A; Yang L; Hartwieg C; Argikar UA; La Bonte LR; Newton R; Kansara V; Flohr S; Hommel U; Jaffee B; Maibaum J
J Med Chem; 2017 Jul; 60(13):5717-5735. PubMed ID: 28621538
[TBL] [Abstract][Full Text] [Related]
7. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
[TBL] [Abstract][Full Text] [Related]
8. 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase.
Torreira E; Tortajada A; Montes T; Rodríguez de Córdoba S; Llorca O
Proc Natl Acad Sci U S A; 2009 Jan; 106(3):882-7. PubMed ID: 19136636
[TBL] [Abstract][Full Text] [Related]
9. Low-molecular weight inhibitors of the alternative complement pathway.
Schubart A; Flohr S; Junt T; Eder J
Immunol Rev; 2023 Jan; 313(1):339-357. PubMed ID: 36217774
[TBL] [Abstract][Full Text] [Related]
10. Complement factor D homolog involved in the alternative complement pathway of rock bream (Oplegnathus fasciatus): Molecular and functional characterization and immune responsive mRNA expression analysis.
Godahewa GI; Perera NC; Bathige SD; Nam BH; Noh JK; Lee J
Fish Shellfish Immunol; 2016 Aug; 55():423-33. PubMed ID: 27311435
[TBL] [Abstract][Full Text] [Related]
11. A bispecific inhibitor of complement and coagulation blocks activation in complementopathy models via a novel mechanism.
Andersen JF; Lei H; Strayer EC; Kanai T; Pham V; Pan XZ; Alvarenga PH; Gerber GF; Asojo OA; Francischetti IMB; Brodsky RA; Valenzuela JG; Ribeiro JMC
Blood; 2023 Jun; 141(25):3109-3121. PubMed ID: 36947859
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule factor D inhibitors targeting the alternative complement pathway.
Maibaum J; Liao SM; Vulpetti A; Ostermann N; Randl S; Rüdisser S; Lorthiois E; Erbel P; Kinzel B; Kolb FA; Barbieri S; Wagner J; Durand C; Fettis K; Dussauge S; Hughes N; Delgado O; Hommel U; Gould T; Mac Sweeney A; Gerhartz B; Cumin F; Flohr S; Schubart A; Jaffee B; Harrison R; Risitano AM; Eder J; Anderson K
Nat Chem Biol; 2016 Dec; 12(12):1105-1110. PubMed ID: 27775713
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway.
Karki RG; Powers J; Mainolfi N; Anderson K; Belanger DB; Liu D; Ji N; Jendza K; Gelin CF; Mac Sweeney A; Solovay C; Delgado O; Crowley M; Liao SM; Argikar UA; Flohr S; La Bonte LR; Lorthiois EL; Vulpetti A; Brown A; Long D; Prentiss M; Gradoux N; de Erkenez A; Cumin F; Adams C; Jaffee B; Mogi M
J Med Chem; 2019 May; 62(9):4656-4668. PubMed ID: 30995036
[TBL] [Abstract][Full Text] [Related]
14. A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models.
Subías M; Tortajada A; Gastoldi S; Galbusera M; López-Perrote A; Lopez Lde J; González-Fernández FA; Villegas-Martínez A; Dominguez M; Llorca O; Noris M; Morgan BP; Rodríguez de Córdoba S
J Immunol; 2014 Dec; 193(11):5567-75. PubMed ID: 25355917
[TBL] [Abstract][Full Text] [Related]
15. Buried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D Inhibitors.
Yang CY; Phillips JG; Stuckey JA; Bai L; Sun H; Delproposto J; Brown WC; Chinnaswamy K
ACS Med Chem Lett; 2016 Dec; 7(12):1092-1096. PubMed ID: 27994744
[TBL] [Abstract][Full Text] [Related]
16. Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases.
Dobó J; Kocsis A; Gál P
Front Immunol; 2018; 9():1851. PubMed ID: 30135690
[TBL] [Abstract][Full Text] [Related]
17. C3(H2O) prevents rescue of complement-mediated C3 glomerulopathy in Cfh-/- Cfd-/- mice.
Zhang Y; Keenan A; Dai DF; May KS; Anderson EE; Lindorfer MA; Henrich JB; Pitcher GR; Taylor RP; Smith RJ
JCI Insight; 2020 May; 5(9):. PubMed ID: 32376801
[TBL] [Abstract][Full Text] [Related]
18. Structures of native and complexed complement factor D: implications of the atypical His57 conformation and self-inhibitory loop in the regulation of specific serine protease activity.
Jing H; Babu YS; Moore D; Kilpatrick JM; Liu XY; Volanakis JE; Narayana SV
J Mol Biol; 1998 Oct; 282(5):1061-81. PubMed ID: 9753554
[TBL] [Abstract][Full Text] [Related]
19. Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis.
Aradottir SS; Kristoffersson AC; Roumenina LT; Bjerre A; Kashioulis P; Palsson R; Karpman D
Front Immunol; 2021; 12():690821. PubMed ID: 34177949
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of factor D of the alternative complement pathway.
Lesavre PH; Müller-Eberhard HJ
J Exp Med; 1978 Dec; 148(6):1498-509. PubMed ID: 82604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
